Yahoo Finance

ELEPHAS BIOSCIENCES AND MITHRL PAIR REAL-TIME TUMOR PROFILING WITH AGENTIC AI TO UNLOCK NEW IMMUNOTHERAPY RESPONSE INSIGHTS

MADISON, Wis., April 16, 2026 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company that has developed the elive™ ex vivo tumor profiling platform, announced a scientific ...
Morningstar

ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY ...

MADISON, Wis., Jan. 8, 2026 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, ...
Morningstar

ELEPHAS BIOSCIENCES ANNOUNCES NEW RESEARCH PARTNERSHIP WITH THE UNIVERSITY OF LOUISVILLE TO STUDY ADVANCED STAGE SOLID CANCER TUMORS IN COLORECTAL ...

Three Investigator-Initiated Trials (IITs) to utilize the Elephas Live™ Platform to evaluate the impact of a combination therapy of surgical intervention and immunotherapy MADISON, Wis., Feb. 23, 2026 ...
BizTimes

Elephas Biosciences raises $40 million to launch predictive immunotherapy platform

Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin. Madison-based Elephas Biosciences Corp. announced Tuesday the ...
ascopubs.org

ELEPHAS-01, ELEPHAS-02 and ELEPHAS-04: Multi-institutional observational prospective clinical trials to assess the accuracy of an ex vivo live tumor fragment platform for ...

A phase 1 first-in-human study of the novel anti-LLT1 antibody (ZM008) alone and in combination with anti-PD1 antibody in patients with advanced solid tumors. Phase II basket study to evaluate the ...